Novartis Shares Plunge After Second Major Drug Trial Fails in a Week

Novartis (NOVN) shares tumbled more than 10% on Tuesday after the company announced its second late-stage clinical trial failure in less than a week, dealing a significant blow to its development pipeline and prompting investors to reassess its near-term growth prospects.

Back-to-Back Pipeline Setbacks

The immediate catalyst for the selloff was the failure of the Phase III HARBOR study for del-desiran, a treatment for myotonic dystrophy type 1 (DM1). According to Novartis, the drug did not meet its primary endpoint of showing a statistically significant improvement in hand muscle stiffness compared to a placebo. The stakes for del-desiran were high, as company leadership had previously projected its peak sales potential could exceed $5 billion.

This news follows a separate announcement from Monday, in which the Phase III Lp(a)HORIZON trial for pelacarsen, a cardiovascular drug, also failed to meet its primary endpoint. The successive failures of two major late-stage assets have clouded the company's regulatory and commercial outlook.

Market Reaction and Outlook

Ad

The stock fell 10.3% to trade at CHF 112.60 in response to the news, marking one of its worst trading sessions in months. The sharp decline reflects investor concern over the erosion of future revenue streams that were expected from the two failed drug candidates.

Despite the clinical setbacks, Novartis reaffirmed its five-year compound annual growth rate (CAGR) guidance of 5–6% for the 2025–2030 period. However, the immediate loss of two potential blockbuster drugs has forced a re-evaluation of the company's pipeline value.

Broader Market Context

The selloff was amplified by a weak broader market environment. European equities were already under pressure amid rising inflation concerns, offering no support for the stock. As a heavyweight in the Swiss Market Index, the plunge in Novartis shares contributed significantly to the index's decline.